Page last updated: 2024-08-24

ursolic acid and Pancreatic Neoplasms

ursolic acid has been researched along with Pancreatic Neoplasms in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's5 (50.00)24.3611
2020's4 (40.00)2.80

Authors

AuthorsStudies
Jing, Y; Leal, AS; Salvador, JA; Wang, R2
Chun, KH; Kim, J; Kim, Y; Lim, JW; Yoon, Y1
Awale, S; Dibwe, DF; Kim, MJ; Omar, AM; Sun, S; Tawila, AM; Toyooka, N; Ueda, JY1
Gubernator, J; Jaromin, A; Markowski, A; Migdał, P; Olczak, E; Pawlik, K; Zaremba-Czogalla, M; Zygmunt, A1
Chen, SY; Li, ZY; Weng, MH; Yen, GC1
Chen, SY; Lin, JA; Lin, JH; Lu, CC; Yen, GC1
Aggarwal, BB; Gupta, SC; Prasad, S; Sung, B; Tyagi, AK; Yadav, VR1
Li, J; Liang, X; Yang, X1
Chadalapaka, G; Jutooru, I; McAlees, A; Safe, S; Stefanac, T1

Other Studies

10 other study(ies) available for ursolic acid and Pancreatic Neoplasms

ArticleYear
Synthesis of novel ursolic acid heterocyclic derivatives with improved abilities of antiproliferation and induction of p53, p21waf1 and NOXA in pancreatic cancer cells.
    Bioorganic & medicinal chemistry, 2012, Oct-01, Volume: 20, Issue:19

    Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Triterpenes; Tumor Suppressor Protein p53; Ursolic Acid

2012
Discovery of ursolic acid prodrug (NX-201): Pharmacokinetics and in vivo antitumor effects in PANC-1 pancreatic cancer.
    Bioorganic & medicinal chemistry letters, 2016, 11-15, Volume: 26, Issue:22

    Topics: Animals; Cell Line, Tumor; Humans; Mice, SCID; Pancreas; Pancreatic Neoplasms; Prodrugs; Triterpenes; Ursolic Acid; Xenograft Model Antitumor Assays

2016
Chemical constituents of Callistemon citrinus from Egypt and their antiausterity activity against PANC-1 human pancreatic cancer cell line.
    Bioorganic & medicinal chemistry letters, 2020, 08-15, Volume: 30, Issue:16

    Topics: Antineoplastic Agents, Phytogenic; Cell Death; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Egypt; Humans; Molecular Structure; Myrtaceae; Pancreatic Neoplasms; Structure-Activity Relationship; Terpenes; Tumor Microenvironment

2020
Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells.
    International journal of molecular sciences, 2022, May-16, Volume: 23, Issue:10

    Topics: Adenocarcinoma; Humans; Lactic Acid; Liposomes; Nanoparticles; Pancreatic Neoplasms; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Triterpenes; Ursolic Acid

2022
Ursolic acid restores sensitivity to gemcitabine through the RAGE/NF-κB/MDR1 axis in pancreatic cancer cells and in a mouse xenograft model.
    Journal of food and drug analysis, 2021, 06-15, Volume: 29, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Heterografts; Humans; Mice; NF-kappa B; Pancreatic Neoplasms; Receptor for Advanced Glycation End Products; Triterpenes; Ursolic Acid

2021
Ursolic acid promotes apoptosis, autophagy, and chemosensitivity in gemcitabine-resistant human pancreatic cancer cells.
    Phytotherapy research : PTR, 2020, Volume: 34, Issue:8

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Humans; Pancreatic Neoplasms; Survival Rate; Triterpenes; Ursolic Acid

2020
Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
    Oncotarget, 2016, Mar-15, Volume: 7, Issue:11

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Inflammation; Mice; Mice, Nude; Pancreatic Neoplasms; Triterpenes; Tumor Microenvironment; Ursolic Acid; Xenograft Model Antitumor Assays

2016
Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways.
    Oncology reports, 2012, Volume: 28, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Nude; NF-kappa B; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Random Allocation; Signal Transduction; Triterpenes; Ursolic Acid; Xenograft Model Antitumor Assays

2012
Semisynthetic ursolic acid fluorolactone derivatives inhibit growth with induction of p21(waf1) and induce apoptosis with upregulation of NOXA and downregulation of c-FLIP in cancer cells.
    ChemMedChem, 2012, Volume: 7, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; G1 Phase; Halogenation; Humans; Lactones; Neoplasms; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Triterpenes; Up-Regulation; Ursolic Acid

2012
Structure-dependent inhibition of bladder and pancreatic cancer cell growth by 2-substituted glycyrrhetinic and ursolic acid derivatives.
    Bioorganic & medicinal chemistry letters, 2008, Apr-15, Volume: 18, Issue:8

    Topics: Cell Line, Tumor; Cell Proliferation; Glycyrrhetinic Acid; Humans; Methylation; Molecular Structure; Pancreatic Neoplasms; Structure-Activity Relationship; Triterpenes; Urinary Bladder Neoplasms; Ursolic Acid

2008